Ionis Pharmaceuticals (IONS) Asset Writedowns and Impairment (2015 - 2026)

Ionis Pharmaceuticals' Asset Writedowns and Impairment history runs 12 years deep, the most recent figure standing at $40000.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 34.43% year-over-year to $40000.0; the TTM figure through Mar 2026 stood at $965000.0 (down 67.4% YoY), while the FY2025 annual figure was $986000.0, down 67.48% from the prior year.
• Asset Writedowns and Impairment was $40000.0 for Q1 2026 at Ionis Pharmaceuticals, down from $4.6 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $4.6 million in Q4 2025 to a low of -$3.9 million in Q3 2025.
• Historically, Asset Writedowns and Impairment has averaged $465294.1 across 5 years, with a median of $256000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Asset Writedowns and Impairment jumped 737.84% in 2024, then slumped 735.48% in 2025.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $875000.0 in 2022, then grew by 11.2% to $973000.0 in 2023, then jumped by 107.91% to $2.0 million in 2024, then soared by 128.82% to $4.6 million in 2025, then tumbled by 99.14% to $40000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $40000.0 (Q1 2026), $4.6 million (Q4 2025), and -$3.9 million (Q3 2025), per Business Quant data.